Pathkey.AI Ltd

Pathkey.AI Ltd has a negative equity position of -268,370 AUD and a debt-to-equity ratio of -1.53, indicating a significant reliance on debt financing and a weak capital structure. The company's liquidity position is further strained by a current ratio of 0.64, suggesting that it may struggle to meet short-term obligations without additional financing. Despite a market cap of 27,318,498.75 AUD, the company's enterprise value to revenue ratio of 994.34 highlights a high valuation relative to its current revenue of 27,780 AUD, which may not be sustainable given its negative operating and net income. The company's profitability is severely challenged, with a net income of -1,447,740 AUD and an operating income of -1,667,160 AUD. Its return on equity of 5.39% is positive but misleading due to the negative equity base, while its return on assets of -2.82% indicates that the company is not generating returns from its asset base. These metrics fall significantly below the industry benchmarks for profitability and returns, which typically require positive and growing net income and strong asset utilization. Pathkey.AI Ltd operates as a single-segment company, with all revenue derived from its AI and predictive analytics solutions for clinical trials and medical research. The company's geographic exposure is not disclosed, but its operations are likely concentrated in Australia given its listing on the Australian Securities Exchange. This lack of geographic diversification increases its vulnerability to local economic and regulatory changes. The company's growth trajectory is uncertain, with a negative operating cash flow of -1,284,290 AUD and a free cash flow of -1,444,910 AUD. These figures suggest that the company is not generating sufficient cash to fund operations or growth initiatives without external financing. The outlook for the current fiscal year is not provided, but the company's historical performance indicates a need for significant improvements in revenue and cost management to achieve positive cash flow. The risk assessment for Pathkey.AI Ltd highlights medium liquidity risk and low dilution risk. The company's negative net cash position after subtracting total debt is a key flag, indicating potential difficulties in maintaining liquidity without additional capital infusions. The dilution risk is low, but the company's reliance on debt financing and negative equity position suggest that it may need to issue new shares in the future to address liquidity constraints. Recent events and filings indicate that the company is in a development phase, with a focus on expanding its AI solutions for clinical trials. The company's recent financial results show a continued loss, with a last actual EPS of -702.36 AUD and a revenue of 250,000.00 AUD. These results underscore the company's need to achieve significant revenue growth and cost control to improve its financial position.